Literature DB >> 25848376

Cutting balloon use may ease the optimal apposition of bioresorbable vascular scaffold in in-stent stenosis.

Ahmet Karabulut1, Yasemin Demirci1.   

Abstract

Bioresorbable vascular scaffolds (BVS) have different mechanical properties as compared to metallic stents. Therefore, the standard procedural technique to achieve appropriate deployment may differ. Utilisation of debulking techniques, including cutting balloon and directional atherectomy prior to BVS deployment, is still questionable. Herein, we discuss a case of coronary in-stent restenosis and reveal the advantage of predilatation of the lesion with cutting balloon prior to BVS deployment.

Entities:  

Keywords:  bioresorbable vascular scaffolds; cutting balloon; optimisation

Year:  2015        PMID: 25848376      PMCID: PMC4372637          DOI: 10.5114/pwki.2015.49190

Source DB:  PubMed          Journal:  Postepy Kardiol Interwencyjnej        ISSN: 1734-9338            Impact factor:   1.426


Introduction

The introduction of bioresorbable vascular scaffold (BVS) started a new era in interventional cardiology [1]. Although the basic deployment techniques of such scaffolds are the same as with metallic stents, because of the relative restriction in post dilatation, preparation of the lesion before the deployment of the BVS is a critical issue. Herein, we discus a case of coronary in-stent restenosis and reveal the advantage of predilatation of the lesion with a cutting balloon prior to BVS deployment.

Case report

A 29-year-old male patient presented with typical angina on exertion. In his medical background, coronary stenting (4.0 × 12 mm bare metal stent (BMS)) had been performed to the proximal left anterior descending artery (LAD) 2 years previously. Due to stent restenosis, another BMS (4.0 × 12 mm) was deployed to an in-stent lesion a year later. The patient was followed with aspirin, clopidogrel, statin, and angiotensin-converting enzyme (ACE) inhibitor. In the final presentation, left ventricular ejection fraction was normal and exercise stress test suggested coronary ischaemia. Coronary angiography showed diffuse in-stent 70–75% stenosis in the LAD (Figure 1). Subsequently, coronary intervention with BVS was scheduled. Cutting balloon was preferred for predilation of the lesion due to extensive diffuse disease and the presence of two overlapping BMSs that could resist the expansion of the new stent/scaffold. After crossing of the lesion, predilatation was performed with 3.5 × 15 cutting balloon at the maximal proposed pressure (Figure 2; note dense and diffuse plaque burden resisting the predilatation), and a 3.5 × 18 BVS (Absorb, Abbot Vascular) was deployed, also with maximal proposed pressure. After post dilation of BVS with a non-compliant balloon, the procedure was terminated with a successful result (Figure 3).
Figure 1

Right anterior oblique caudal view of left coronary arteries. This image shows proximal in-stent stenosis of the left anterior descending artery. Arrows indicate the edge of previous stents

Figure 2

Cutting balloon dilatation (A) and resorption of in-stent plaque after pre-dilatation (B)

Figure 3

BVS deployment (A) and final image (B). Note that the final image of the proximal left anterior descending artery resembles the image taken after cutting balloon dilatation

Right anterior oblique caudal view of left coronary arteries. This image shows proximal in-stent stenosis of the left anterior descending artery. Arrows indicate the edge of previous stents Cutting balloon dilatation (A) and resorption of in-stent plaque after pre-dilatation (B) BVS deployment (A) and final image (B). Note that the final image of the proximal left anterior descending artery resembles the image taken after cutting balloon dilatation

Discussion

Bioresorbable vascular scaffolds have different mechanical properties as compared to metallic stents. Thus, the standard procedural technique to achieve appropriate deployment may differ [2]. Incomplete scaffold apposition and uncovered struts are related to higher risk of scaffold thrombosis [3]. Therefore, quantitative angiography with optical coherence tomography (OCT) or intravascular ultrasounds (IVUS) is preferred in order to achieve optimal apposition [3, 4]. Usage of BVS in complex coronary lesions is still challenging because of the unique texture [5]. Utilisation of debulking techniques, including cutting balloon and directional atherectomy prior to BVS deployment, is also questionable. Herein, we show that prior cutting balloon dilatation is useful and may facilitate optimal BVS apposition. Lack of OCT or IVUS analysis is a major criticism of our proposal. However, the similarity of both images taken after cutting balloon dilatation and BVS deployment may serve as reliable supportive evidence for our statement. The significance of the routine use of a debulking technique prior to BVS deployment has no yet been reported. Further series and studies may clarify these statements more clearly.

Conclusions

Lesion preparation before BVS deployment is a crucial point. Use of a debulking technique including cutting balloon predilatation may facilitate optimal BVS apposition.
  5 in total

1.  Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study.

Authors:  Josep Gomez-Lara; Roberto Diletti; Salvatore Brugaletta; Yoshinobu Onuma; Vasim Farooq; Leif Thuesen; Dougal McClean; Jacques Koolen; John A Ormiston; Stefan Windecker; Robert Whitbourn; Dariusz Dudek; Cécile Dorange; Susan Veldhof; Richard Rapoza; Evelyn Regar; Hector M Garcia-Garcia; Patrick W Serruys
Journal:  EuroIntervention       Date:  2012-06-20       Impact factor: 6.534

Review 2.  Design principles and performance of bioresorbable polymeric vascular scaffolds.

Authors:  James P Oberhauser; Syed Hossainy; Richard J Rapoza
Journal:  EuroIntervention       Date:  2009-12-15       Impact factor: 6.534

3.  Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque?

Authors:  Salvatore Brugaletta; Maria D Radu; Hector M Garcia-Garcia; Jung Ho Heo; Vasim Farooq; Chrysafios Girasis; Robert-Jan van Geuns; Leif Thuesen; Dougal McClean; Bernard Chevalier; Stephan Windecker; Jacques Koolen; Richard Rapoza; Karine Miquel-Hebert; John Ormiston; Patrick W Serruys
Journal:  Atherosclerosis       Date:  2011-12-13       Impact factor: 5.162

4.  Serial analysis of the malapposed and uncovered struts of the new generation of everolimus-eluting bioresorbable scaffold with optical coherence tomography.

Authors:  Josep Gomez-Lara; Maria Radu; Salvatore Brugaletta; Vasim Farooq; Roberto Diletti; Yoshinobu Onuma; Stephan Windecker; Leif Thuesen; Dougal McClean; Jacques Koolen; Robert Whitbourn; Dariusz Dudek; Pieter C Smits; Evelyn Regar; Susan Veldhof; Richard Rapoza; John A Ormiston; Hector M Garcia-Garcia; Patrick W Serruys
Journal:  JACC Cardiovasc Interv       Date:  2011-09       Impact factor: 11.195

5.  Delivery of a bioresorbable vascular scaffold to complex lesions.

Authors:  Felix Meincke; Karl-Heinz Kuck; Martin W Bergmann
Journal:  Catheter Cardiovasc Interv       Date:  2014-07-30       Impact factor: 2.692

  5 in total
  3 in total

1.  Twelve months clinical outcome after bioresorbable vascular scaffold implantation in patients with stable angina and acute coronary syndrome. Data from the Polish National Registry.

Authors:  Łukasz Rzeszutko; Zbigniew Siudak; Tomasz Tokarek; Krzysztof Plens; Adrian Włodarczak; Andrzej Lekston; Andrzej Ochała; Robert J Gil; Wojciech Balak; Dariusz Dudek
Journal:  Postepy Kardiol Interwencyjnej       Date:  2016-05-11       Impact factor: 1.426

2.  Patient profile and periprocedural outcomes of bioresorbable vascular scaffold implantation in comparison with drug-eluting and bare-metal stent implantation. Experience from ORPKI Polish National Registry 2014-2015.

Authors:  Łukasz Rzeszutko; Tomasz Tokarek; Zbigniew Siudak; Artur Dziewierz; Krzysztof Żmudka; Dariusz Dudek
Journal:  Postepy Kardiol Interwencyjnej       Date:  2016-11-17       Impact factor: 1.426

3.  Balloon postdilatation is a mandatory step in the deployment of bioresorbable vascular scaffold.

Authors:  Ahmet Karabulut
Journal:  Anatol J Cardiol       Date:  2017-01       Impact factor: 1.596

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.